These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 27552906

  • 1. Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.
    Farkas Á, Jókay Á, Balásházy I, Füri P, Müller V, Tomisa G, Horváth A.
    Eur J Pharm Sci; 2016 Oct 10; 93():371-9. PubMed ID: 27552906
    [Abstract] [Full Text] [Related]

  • 2. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
    Horváth A, Farkas Á, Szipőcs A, Tomisa G, Szalai Z, Gálffy G.
    Eur J Pharm Sci; 2020 Nov 01; 154():105508. PubMed ID: 32836137
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort® (budesonide/formoterol) pressurized metered dose inhaler.
    Gillen M, Forte P, Svensson JO, Lamarca R, Burke J, Rask K, Larsdotter Nilsson U, Eckerwall G.
    Pulm Pharmacol Ther; 2018 Oct 01; 52():7-17. PubMed ID: 30077809
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Experimental and computational study of the effect of breath-actuated mechanism built in the NEXThaler® dry powder inhaler.
    Farkas Á, Lewis D, Church T, Tweedie A, Mason F, Haddrell AE, Reid JP, Horváth A, Balásházy I.
    Int J Pharm; 2017 Nov 25; 533(1):225-235. PubMed ID: 28941830
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study.
    Janson C, Lööf T, Telg G, Stratelis G, Nilsson F.
    NPJ Prim Care Respir Med; 2016 Nov 17; 26():16053. PubMed ID: 27853177
    [Abstract] [Full Text] [Related]

  • 15. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
    Chrystyn H, Safioti G, Keegstra JR, Gopalan G.
    Int J Pharm; 2015 Aug 01; 491(1-2):268-76. PubMed ID: 26043823
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.
    Cazzola M, Ora J, Di Paolo A, Puxeddu E, Calzetta L, Rogliani P.
    Pulm Pharmacol Ther; 2016 Aug 01; 39():48-53. PubMed ID: 27344046
    [Abstract] [Full Text] [Related]

  • 18. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
    Bagherisadeghi G, Chrystyn H, Abadelah M, Larhrib EH.
    Eur J Pharm Sci; 2019 Nov 01; 139():105059. PubMed ID: 31472254
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.